| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 97 | 2024 | 5671 | 5.100 |
Why?
|
| Bone Marrow Transplantation | 78 | 2024 | 2690 | 4.780 |
Why?
|
| Transplantation Conditioning | 63 | 2023 | 1590 | 3.590 |
Why?
|
| Transplantation Chimera | 28 | 2022 | 593 | 2.530 |
Why?
|
| Graft vs Host Disease | 68 | 2024 | 3026 | 2.300 |
Why?
|
| Cord Blood Stem Cell Transplantation | 18 | 2020 | 305 | 2.290 |
Why?
|
| Hematologic Neoplasms | 32 | 2021 | 1896 | 2.250 |
Why?
|
| Kidney Transplantation | 22 | 2023 | 4218 | 1.310 |
Why?
|
| Transplantation, Homologous | 49 | 2021 | 4802 | 1.220 |
Why?
|
| Histocompatibility Testing | 19 | 2019 | 711 | 1.160 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 10 | 2020 | 225 | 1.090 |
Why?
|
| Kidney Failure, Chronic | 11 | 2019 | 2474 | 1.090 |
Why?
|
| HLA Antigens | 11 | 2019 | 1327 | 1.060 |
Why?
|
| Transplantation Tolerance | 8 | 2023 | 605 | 1.010 |
Why?
|
| Tissue Donors | 12 | 2018 | 2329 | 0.990 |
Why?
|
| Hematologic Diseases | 5 | 2023 | 496 | 0.990 |
Why?
|
| Transplantation, Autologous | 30 | 2017 | 2112 | 0.890 |
Why?
|
| Stem Cell Transplantation | 12 | 2015 | 1600 | 0.870 |
Why?
|
| Bone Marrow | 12 | 2024 | 2909 | 0.810 |
Why?
|
| Cyclophosphamide | 21 | 2023 | 2218 | 0.800 |
Why?
|
| Myeloablative Agonists | 7 | 2018 | 209 | 0.780 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 9 | 2020 | 629 | 0.780 |
Why?
|
| Whole-Body Irradiation | 12 | 2019 | 432 | 0.700 |
Why?
|
| Busulfan | 11 | 2015 | 258 | 0.680 |
Why?
|
| Histocompatibility | 5 | 2012 | 317 | 0.650 |
Why?
|
| Leukemia | 15 | 2018 | 1520 | 0.650 |
Why?
|
| Swine, Miniature | 12 | 2015 | 961 | 0.640 |
Why?
|
| Leukemia, Myeloid, Acute | 13 | 2019 | 3611 | 0.610 |
Why?
|
| Multiple Myeloma | 11 | 2019 | 5144 | 0.580 |
Why?
|
| Fetal Blood | 8 | 2019 | 1347 | 0.580 |
Why?
|
| Bone Marrow Cells | 9 | 2024 | 2409 | 0.580 |
Why?
|
| Immune Tolerance | 13 | 2019 | 2298 | 0.560 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 7 | 2018 | 263 | 0.560 |
Why?
|
| Graft Survival | 20 | 2019 | 3814 | 0.520 |
Why?
|
| Blood Donors | 7 | 2020 | 345 | 0.500 |
Why?
|
| Lymphocyte Transfusion | 6 | 2018 | 232 | 0.500 |
Why?
|
| Lymphoma | 12 | 2022 | 1899 | 0.490 |
Why?
|
| Chimerism | 5 | 2023 | 155 | 0.460 |
Why?
|
| Hematopoietic Stem Cells | 8 | 2020 | 3394 | 0.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2015 | 11735 | 0.430 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2014 | 1372 | 0.430 |
Why?
|
| Haplotypes | 8 | 2012 | 2713 | 0.430 |
Why?
|
| Haploidy | 4 | 2010 | 126 | 0.400 |
Why?
|
| HLA-A2 Antigen | 1 | 2012 | 209 | 0.400 |
Why?
|
| Sarcoma, Myeloid | 1 | 2012 | 52 | 0.390 |
Why?
|
| Transplantation Immunology | 7 | 2015 | 532 | 0.380 |
Why?
|
| Humans | 218 | 2024 | 760740 | 0.370 |
Why?
|
| Transplants | 2 | 2016 | 206 | 0.360 |
Why?
|
| Nausea | 3 | 2000 | 679 | 0.360 |
Why?
|
| Hepatic Veno-Occlusive Disease | 6 | 2010 | 220 | 0.340 |
Why?
|
| Middle Aged | 111 | 2024 | 220603 | 0.340 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2005 | 121 | 0.340 |
Why?
|
| Adult | 118 | 2024 | 220995 | 0.340 |
Why?
|
| Organ Transplantation | 2 | 2015 | 1157 | 0.320 |
Why?
|
| Affect | 5 | 2019 | 1486 | 0.320 |
Why?
|
| Tumor Escape | 1 | 2012 | 371 | 0.320 |
Why?
|
| Disease-Free Survival | 17 | 2019 | 6807 | 0.320 |
Why?
|
| Capillary Leak Syndrome | 3 | 2011 | 34 | 0.320 |
Why?
|
| Myelodysplastic Syndromes | 7 | 2018 | 1394 | 0.310 |
Why?
|
| T-Lymphocytes | 17 | 2018 | 10175 | 0.310 |
Why?
|
| Graft vs Tumor Effect | 2 | 2008 | 68 | 0.290 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2008 | 79 | 0.290 |
Why?
|
| Female | 123 | 2024 | 392203 | 0.280 |
Why?
|
| Ondansetron | 2 | 2000 | 95 | 0.280 |
Why?
|
| Male | 117 | 2024 | 360402 | 0.280 |
Why?
|
| Combined Modality Therapy | 22 | 2021 | 8516 | 0.270 |
Why?
|
| Lymphocytes | 5 | 2018 | 2604 | 0.270 |
Why?
|
| Anemia, Aplastic | 4 | 1996 | 230 | 0.270 |
Why?
|
| Vascular Diseases | 1 | 2015 | 1159 | 0.270 |
Why?
|
| Vidarabine | 6 | 2019 | 336 | 0.260 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 1878 | 0.260 |
Why?
|
| Graft Rejection | 13 | 2015 | 4438 | 0.250 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 808 | 0.250 |
Why?
|
| Quality of Life | 10 | 2020 | 13359 | 0.250 |
Why?
|
| Immunosuppressive Agents | 8 | 2019 | 4172 | 0.250 |
Why?
|
| Antilymphocyte Serum | 6 | 2016 | 485 | 0.240 |
Why?
|
| Paraproteinemias | 3 | 2015 | 248 | 0.240 |
Why?
|
| Aged | 64 | 2024 | 169092 | 0.240 |
Why?
|
| Parathyroid Hormone | 2 | 2012 | 1803 | 0.240 |
Why?
|
| Melphalan | 6 | 2019 | 420 | 0.240 |
Why?
|
| Etoposide | 5 | 2012 | 634 | 0.240 |
Why?
|
| Isoantibodies | 3 | 2014 | 669 | 0.240 |
Why?
|
| Carboplatin | 5 | 2002 | 793 | 0.230 |
Why?
|
| Primary Myelofibrosis | 3 | 2023 | 209 | 0.230 |
Why?
|
| Gene Deletion | 1 | 2012 | 2659 | 0.230 |
Why?
|
| Tissue and Organ Harvesting | 3 | 2024 | 373 | 0.220 |
Why?
|
| Hodgkin Disease | 3 | 2011 | 1378 | 0.220 |
Why?
|
| Physicians | 1 | 2022 | 4583 | 0.220 |
Why?
|
| Interleukin-2 | 7 | 2003 | 1888 | 0.220 |
Why?
|
| Endothelium, Vascular | 2 | 2015 | 4433 | 0.220 |
Why?
|
| Niacinamide | 2 | 2016 | 413 | 0.220 |
Why?
|
| Isoantigens | 1 | 2005 | 551 | 0.220 |
Why?
|
| Lymphocyte Depletion | 8 | 2016 | 601 | 0.210 |
Why?
|
| Vomiting | 2 | 1998 | 651 | 0.210 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2019 | 1551 | 0.200 |
Why?
|
| Syndrome | 5 | 2015 | 3268 | 0.200 |
Why?
|
| Recurrence | 10 | 2020 | 8426 | 0.200 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2008 | 2197 | 0.200 |
Why?
|
| Phenylurea Compounds | 2 | 2016 | 529 | 0.200 |
Why?
|
| Acute Disease | 15 | 2024 | 7236 | 0.200 |
Why?
|
| Quality of Health Care | 1 | 2017 | 4325 | 0.200 |
Why?
|
| Survival Analysis | 16 | 2018 | 10072 | 0.200 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2016 | 495 | 0.190 |
Why?
|
| Swine | 16 | 2016 | 5908 | 0.190 |
Why?
|
| Swine Diseases | 2 | 2012 | 61 | 0.190 |
Why?
|
| Nepal | 1 | 2022 | 304 | 0.180 |
Why?
|
| Remission Induction | 8 | 2016 | 2391 | 0.180 |
Why?
|
| Granisetron | 1 | 2000 | 7 | 0.180 |
Why?
|
| Mycoses | 3 | 2013 | 386 | 0.180 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2022 | 915 | 0.180 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 299 | 0.170 |
Why?
|
| Antiemetics | 2 | 2000 | 186 | 0.170 |
Why?
|
| Immunoconjugates | 2 | 2018 | 951 | 0.170 |
Why?
|
| Anxiety | 5 | 2020 | 4573 | 0.170 |
Why?
|
| Pneumocystis | 1 | 1999 | 55 | 0.170 |
Why?
|
| Living Donors | 3 | 2018 | 642 | 0.170 |
Why?
|
| Tandem Repeat Sequences | 2 | 2016 | 180 | 0.170 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2020 | 130 | 0.170 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 1993 | 664 | 0.170 |
Why?
|
| Naphthoquinones | 1 | 1999 | 58 | 0.170 |
Why?
|
| Treatment Outcome | 34 | 2024 | 64572 | 0.160 |
Why?
|
| Salvage Therapy | 4 | 2009 | 1263 | 0.160 |
Why?
|
| Somatostatin | 1 | 2021 | 447 | 0.160 |
Why?
|
| Pilot Projects | 8 | 2024 | 8619 | 0.160 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 687 | 0.160 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2022 | 1467 | 0.160 |
Why?
|
| Immunologic Memory | 3 | 2015 | 1355 | 0.160 |
Why?
|
| Kidney Diseases | 4 | 2015 | 2090 | 0.160 |
Why?
|
| Arthritis, Gouty | 1 | 1998 | 28 | 0.150 |
Why?
|
| Palliative Care | 3 | 2017 | 3593 | 0.150 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1999 | 242 | 0.150 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2022 | 301 | 0.150 |
Why?
|
| Leukocyte Transfusion | 3 | 2003 | 56 | 0.140 |
Why?
|
| Thymus Gland | 4 | 2010 | 1243 | 0.140 |
Why?
|
| Flow Cytometry | 9 | 2015 | 5863 | 0.140 |
Why?
|
| Retrospective Studies | 31 | 2024 | 80583 | 0.140 |
Why?
|
| Caregivers | 3 | 2020 | 2241 | 0.140 |
Why?
|
| Nursing Assessment | 2 | 1994 | 106 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 8 | 2010 | 9171 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2010 | 2252 | 0.130 |
Why?
|
| Intestinal Diseases | 2 | 2012 | 503 | 0.130 |
Why?
|
| HLA-C Antigens | 1 | 2016 | 140 | 0.130 |
Why?
|
| Adolescent | 36 | 2019 | 88247 | 0.130 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2017 | 123 | 0.130 |
Why?
|
| Bacteremia | 2 | 2020 | 977 | 0.130 |
Why?
|
| Anemia | 3 | 2017 | 1504 | 0.130 |
Why?
|
| Survival Rate | 13 | 2019 | 12719 | 0.130 |
Why?
|
| Staphylococcal Protein A | 2 | 1985 | 39 | 0.130 |
Why?
|
| Arabinonucleosides | 1 | 2015 | 34 | 0.130 |
Why?
|
| Cytapheresis | 1 | 2015 | 8 | 0.130 |
Why?
|
| Polydeoxyribonucleotides | 2 | 2010 | 136 | 0.130 |
Why?
|
| Depression | 6 | 2020 | 8132 | 0.130 |
Why?
|
| Breast Neoplasms | 6 | 2012 | 20988 | 0.130 |
Why?
|
| Adenine Nucleotides | 1 | 2015 | 111 | 0.130 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 115 | 0.120 |
Why?
|
| Blood Specimen Collection | 1 | 2016 | 238 | 0.120 |
Why?
|
| Dyskeratosis Congenita | 1 | 2015 | 73 | 0.120 |
Why?
|
| Animals | 33 | 2023 | 168202 | 0.120 |
Why?
|
| Antineoplastic Agents | 6 | 2016 | 13635 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2017 | 4570 | 0.120 |
Why?
|
| Decidua | 1 | 2015 | 82 | 0.120 |
Why?
|
| Chimera | 2 | 1999 | 453 | 0.120 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2015 | 121 | 0.120 |
Why?
|
| Young Adult | 23 | 2020 | 59191 | 0.120 |
Why?
|
| Incidence | 7 | 2023 | 21339 | 0.120 |
Why?
|
| Antifungal Agents | 1 | 1999 | 753 | 0.120 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2018 | 361 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 2546 | 0.120 |
Why?
|
| Dermatitis, Exfoliative | 1 | 2014 | 27 | 0.120 |
Why?
|
| Environment, Controlled | 1 | 1994 | 42 | 0.120 |
Why?
|
| Polycythemia | 1 | 2015 | 124 | 0.110 |
Why?
|
| Models, Animal | 4 | 2017 | 2108 | 0.110 |
Why?
|
| Urate Oxidase | 1 | 2014 | 31 | 0.110 |
Why?
|
| Immunity, Cellular | 2 | 2012 | 1550 | 0.110 |
Why?
|
| Fever | 2 | 2014 | 1618 | 0.110 |
Why?
|
| Respiratory Insufficiency | 3 | 2021 | 1230 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 1700 | 0.110 |
Why?
|
| Platelet Transfusion | 2 | 2000 | 298 | 0.110 |
Why?
|
| Patient Isolation | 1 | 1994 | 100 | 0.110 |
Why?
|
| Drug Administration Schedule | 7 | 2014 | 4845 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2015 | 547 | 0.110 |
Why?
|
| Stress, Psychological | 2 | 2019 | 4488 | 0.110 |
Why?
|
| Cyclosporine | 4 | 2016 | 776 | 0.110 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 39062 | 0.110 |
Why?
|
| Pulmonary Edema | 3 | 2014 | 407 | 0.100 |
Why?
|
| Radiotherapy | 2 | 1998 | 1497 | 0.100 |
Why?
|
| Animals, Laboratory | 1 | 2012 | 46 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2021 | 1202 | 0.100 |
Why?
|
| Integrin alpha4 | 1 | 2012 | 87 | 0.100 |
Why?
|
| Integrin beta Chains | 1 | 2012 | 115 | 0.100 |
Why?
|
| Neoplasms | 13 | 2020 | 22131 | 0.100 |
Why?
|
| Somatosensory Disorders | 1 | 2012 | 49 | 0.100 |
Why?
|
| Species Specificity | 2 | 2015 | 2410 | 0.100 |
Why?
|
| Endometrium | 1 | 2015 | 403 | 0.100 |
Why?
|
| Specimen Handling | 2 | 1994 | 701 | 0.100 |
Why?
|
| Carmustine | 1 | 2012 | 137 | 0.100 |
Why?
|
| Respirovirus Infections | 1 | 2011 | 51 | 0.100 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 656 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2014 | 617 | 0.100 |
Why?
|
| Blood Banks | 1 | 2012 | 108 | 0.100 |
Why?
|
| Time Factors | 13 | 2015 | 39908 | 0.100 |
Why?
|
| Leukocytosis | 2 | 2009 | 251 | 0.100 |
Why?
|
| Antigens, CD34 | 3 | 2020 | 658 | 0.090 |
Why?
|
| Neutropenia | 2 | 2003 | 885 | 0.090 |
Why?
|
| B-Lymphocytes | 5 | 2015 | 4745 | 0.090 |
Why?
|
| Progesterone | 1 | 2015 | 742 | 0.090 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2015 | 376 | 0.090 |
Why?
|
| Erythropoietin | 1 | 2015 | 719 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2017 | 3077 | 0.090 |
Why?
|
| Multiple Organ Failure | 3 | 2010 | 387 | 0.090 |
Why?
|
| Health Resources | 1 | 2016 | 934 | 0.090 |
Why?
|
| Recombinant Proteins | 8 | 2014 | 6520 | 0.090 |
Why?
|
| Immunocompromised Host | 2 | 2012 | 858 | 0.090 |
Why?
|
| Infusions, Intravenous | 6 | 2014 | 2214 | 0.090 |
Why?
|
| Stem Cells | 2 | 2018 | 3514 | 0.090 |
Why?
|
| Immunization, Passive | 1 | 1992 | 616 | 0.090 |
Why?
|
| Bacterial Infections | 3 | 1998 | 1389 | 0.090 |
Why?
|
| Stomatitis | 1 | 1992 | 271 | 0.080 |
Why?
|
| Child, Preschool | 17 | 2019 | 42193 | 0.080 |
Why?
|
| Misonidazole | 1 | 1989 | 33 | 0.080 |
Why?
|
| Drug Evaluation | 7 | 2000 | 641 | 0.080 |
Why?
|
| Methotrexate | 4 | 2015 | 1716 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2016 | 5672 | 0.080 |
Why?
|
| Agranulocytosis | 1 | 1989 | 97 | 0.080 |
Why?
|
| Serotonin Antagonists | 2 | 2000 | 144 | 0.080 |
Why?
|
| Hematopoiesis | 5 | 2005 | 2049 | 0.080 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2017 | 4575 | 0.080 |
Why?
|
| Amphotericin B | 1 | 1989 | 142 | 0.080 |
Why?
|
| Escherichia coli Infections | 1 | 2012 | 518 | 0.080 |
Why?
|
| Thioguanine | 1 | 1988 | 45 | 0.080 |
Why?
|
| Edema | 1 | 2012 | 765 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 3 | 2010 | 827 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2017 | 2242 | 0.080 |
Why?
|
| Estrogens | 1 | 2015 | 1521 | 0.080 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2009 | 285 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 2014 | 611 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 11874 | 0.070 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2007 | 27 | 0.070 |
Why?
|
| Mitoxantrone | 1 | 1987 | 148 | 0.070 |
Why?
|
| Ovarian Neoplasms | 4 | 2001 | 4849 | 0.070 |
Why?
|
| Sirolimus | 2 | 2015 | 1533 | 0.070 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 1991 | 385 | 0.070 |
Why?
|
| Filgrastim | 1 | 2007 | 132 | 0.070 |
Why?
|
| Fibrinolytic Agents | 2 | 2010 | 2073 | 0.070 |
Why?
|
| Cell Separation | 4 | 2016 | 1718 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2012 | 10754 | 0.070 |
Why?
|
| Viremia | 1 | 2010 | 706 | 0.070 |
Why?
|
| Batroxobin | 1 | 1986 | 4 | 0.070 |
Why?
|
| Kidney | 3 | 2019 | 7044 | 0.070 |
Why?
|
| Chronic Disease | 6 | 2020 | 9310 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2009 | 1797 | 0.070 |
Why?
|
| Postoperative Complications | 5 | 2019 | 15609 | 0.060 |
Why?
|
| Cytokines | 5 | 2015 | 7373 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2012 | 1434 | 0.060 |
Why?
|
| Erythrocyte Transfusion | 1 | 1990 | 568 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 3164 | 0.060 |
Why?
|
| Killer Cells, Natural | 2 | 2005 | 2191 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2010 | 748 | 0.060 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1986 | 186 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2011 | 2509 | 0.060 |
Why?
|
| Morbidity | 1 | 2010 | 1750 | 0.060 |
Why?
|
| Leukemia, Myeloid | 3 | 2006 | 693 | 0.060 |
Why?
|
| Immunoglobulin G | 3 | 1992 | 4533 | 0.060 |
Why?
|
| Infection Control | 1 | 1992 | 982 | 0.060 |
Why?
|
| Leukocyte Count | 3 | 2015 | 1597 | 0.060 |
Why?
|
| Integrins | 1 | 2009 | 834 | 0.060 |
Why?
|
| Disease Management | 1 | 2015 | 2506 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 7390 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 1994 | 2419 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 3730 | 0.060 |
Why?
|
| Child | 19 | 2019 | 80089 | 0.060 |
Why?
|
| Butanols | 1 | 2004 | 19 | 0.060 |
Why?
|
| Defoliants, Chemical | 1 | 1984 | 9 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2015 | 4140 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 4252 | 0.060 |
Why?
|
| Clostridium | 1 | 2004 | 100 | 0.060 |
Why?
|
| Amyloidosis | 1 | 2010 | 815 | 0.060 |
Why?
|
| Osteolysis | 1 | 1985 | 275 | 0.060 |
Why?
|
| Protozoan Infections | 1 | 2003 | 38 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 1994 | 2164 | 0.050 |
Why?
|
| Herbicides | 1 | 1984 | 105 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2005 | 512 | 0.050 |
Why?
|
| Prognosis | 5 | 2015 | 29601 | 0.050 |
Why?
|
| Blood | 1 | 1985 | 596 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2014 | 2722 | 0.050 |
Why?
|
| Heat-Shock Response | 1 | 2004 | 179 | 0.050 |
Why?
|
| Peptide Hydrolases | 1 | 1986 | 624 | 0.050 |
Why?
|
| Genes, bcl-2 | 1 | 2023 | 119 | 0.050 |
Why?
|
| Major Histocompatibility Complex | 2 | 2017 | 870 | 0.050 |
Why?
|
| Cytarabine | 3 | 2014 | 697 | 0.050 |
Why?
|
| Hypercalcemia | 1 | 1985 | 423 | 0.050 |
Why?
|
| Hospitals, University | 2 | 2016 | 565 | 0.050 |
Why?
|
| Adenocarcinoma | 3 | 1999 | 6345 | 0.050 |
Why?
|
| Immunophenotyping | 3 | 2011 | 1864 | 0.050 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2005 | 461 | 0.050 |
Why?
|
| Transplantation, Heterologous | 3 | 1999 | 2382 | 0.050 |
Why?
|
| Family | 2 | 2007 | 3193 | 0.050 |
Why?
|
| Heart Transplantation | 2 | 2010 | 3233 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2015 | 18220 | 0.050 |
Why?
|
| Lymphopoiesis | 1 | 2002 | 133 | 0.050 |
Why?
|
| Thiotepa | 2 | 2014 | 66 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 2005 | 1972 | 0.050 |
Why?
|
| Bone Resorption | 1 | 1985 | 723 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2005 | 1146 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 10203 | 0.050 |
Why?
|
| Liver | 2 | 2015 | 7512 | 0.050 |
Why?
|
| Aspergillosis | 1 | 2003 | 242 | 0.050 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2003 | 238 | 0.050 |
Why?
|
| Biopsy | 5 | 2015 | 6763 | 0.050 |
Why?
|
| Graft vs Host Reaction | 1 | 2001 | 99 | 0.050 |
Why?
|
| Ovary | 1 | 2005 | 959 | 0.050 |
Why?
|
| Transplantation, Isogeneic | 1 | 2001 | 248 | 0.050 |
Why?
|
| Clinical Trials as Topic | 3 | 2002 | 7995 | 0.040 |
Why?
|
| Primates | 1 | 2023 | 521 | 0.040 |
Why?
|
| Oocytes | 1 | 2005 | 1166 | 0.040 |
Why?
|
| Lymphocyte Activation | 3 | 2014 | 5463 | 0.040 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2000 | 57 | 0.040 |
Why?
|
| Anemia, Hemolytic | 1 | 1981 | 162 | 0.040 |
Why?
|
| Mice | 9 | 2012 | 81368 | 0.040 |
Why?
|
| Minisatellite Repeats | 1 | 2001 | 163 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 1989 | 1156 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 2851 | 0.040 |
Why?
|
| Cyclosporins | 2 | 1991 | 216 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 1405 | 0.040 |
Why?
|
| Pneumonia | 1 | 2012 | 2143 | 0.040 |
Why?
|
| Hospitalization | 5 | 2017 | 10708 | 0.040 |
Why?
|
| Atovaquone | 1 | 1999 | 56 | 0.040 |
Why?
|
| Infant | 9 | 2016 | 36157 | 0.040 |
Why?
|
| DNA Primers | 3 | 2012 | 2817 | 0.040 |
Why?
|
| Risk Factors | 7 | 2019 | 74128 | 0.040 |
Why?
|
| Cell Lineage | 2 | 2006 | 2553 | 0.040 |
Why?
|
| Neutrophils | 3 | 2016 | 3763 | 0.040 |
Why?
|
| Solubility | 2 | 2012 | 1089 | 0.040 |
Why?
|
| Survivors | 2 | 2024 | 2373 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 693 | 0.040 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2001 | 258 | 0.040 |
Why?
|
| Tacrolimus | 2 | 2015 | 733 | 0.040 |
Why?
|
| Cryopreservation | 2 | 2016 | 728 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2018 | 5239 | 0.040 |
Why?
|
| Plasminogen Activators | 2 | 1997 | 199 | 0.040 |
Why?
|
| Prospective Studies | 8 | 2018 | 54364 | 0.040 |
Why?
|
| Lymphoma, Follicular | 1 | 2003 | 457 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 424 | 0.040 |
Why?
|
| Thyroglobulin | 1 | 2019 | 111 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2011 | 3037 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 1923 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2003 | 1349 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 5334 | 0.040 |
Why?
|
| Antibodies, Heterophile | 1 | 1999 | 128 | 0.040 |
Why?
|
| Bone Marrow Purging | 1 | 1998 | 108 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2012 | 1348 | 0.040 |
Why?
|
| Neoplasm Metastasis | 3 | 2000 | 4910 | 0.040 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 1 | 1998 | 44 | 0.040 |
Why?
|
| Ciprofloxacin | 1 | 2020 | 312 | 0.040 |
Why?
|
| Penicillins | 1 | 1981 | 402 | 0.040 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2004 | 1131 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 2000 | 472 | 0.040 |
Why?
|
| Leukapheresis | 2 | 2012 | 134 | 0.040 |
Why?
|
| Ursodeoxycholic Acid | 1 | 1997 | 81 | 0.040 |
Why?
|
| Cell Count | 2 | 2009 | 1834 | 0.040 |
Why?
|
| Hormones | 1 | 2021 | 869 | 0.040 |
Why?
|
| Receptors, Serotonin | 1 | 1998 | 208 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2018 | 4365 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 4021 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2003 | 718 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 1989 | 2533 | 0.030 |
Why?
|
| Spleen | 1 | 2023 | 2286 | 0.030 |
Why?
|
| Registries | 3 | 2016 | 8209 | 0.030 |
Why?
|
| Vincristine | 2 | 2010 | 1036 | 0.030 |
Why?
|
| Pulmonary Fibrosis | 4 | 1991 | 505 | 0.030 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 2632 | 0.030 |
Why?
|
| Liver Failure | 1 | 1998 | 250 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 1788 | 0.030 |
Why?
|
| Fatigue | 2 | 2016 | 1550 | 0.030 |
Why?
|
| Nitriles | 1 | 2021 | 971 | 0.030 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 2315 | 0.030 |
Why?
|
| Pedigree | 2 | 2015 | 4539 | 0.030 |
Why?
|
| Skin Diseases | 3 | 2012 | 1094 | 0.030 |
Why?
|
| Inpatients | 2 | 2017 | 2545 | 0.030 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 1996 | 97 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 2002 | 938 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 637 | 0.030 |
Why?
|
| Killer Cells, Lymphokine-Activated | 2 | 1992 | 42 | 0.030 |
Why?
|
| Longitudinal Studies | 3 | 2015 | 14599 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 883 | 0.030 |
Why?
|
| Bangladesh | 1 | 2016 | 732 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 1994 | 361 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2010 | 9277 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 524 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2010 | 41464 | 0.030 |
Why?
|
| Benzylamines | 1 | 2015 | 246 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 2015 | 245 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1999 | 1202 | 0.030 |
Why?
|
| Biological Availability | 1 | 1994 | 389 | 0.030 |
Why?
|
| Ileal Diseases | 1 | 1994 | 68 | 0.030 |
Why?
|
| Infant, Newborn | 4 | 2016 | 26183 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 422 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 2 | 1997 | 1163 | 0.030 |
Why?
|
| Half-Life | 1 | 1994 | 650 | 0.030 |
Why?
|
| Administration, Oral | 2 | 1994 | 4010 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2000 | 12333 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2015 | 22153 | 0.030 |
Why?
|
| Safety | 1 | 1998 | 1149 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 5811 | 0.030 |
Why?
|
| Embryo Implantation | 1 | 2015 | 270 | 0.030 |
Why?
|
| Massachusetts | 2 | 2017 | 8835 | 0.030 |
Why?
|
| Papio | 3 | 1999 | 669 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1661 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 2 | 2006 | 351 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 1998 | 2897 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 3798 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2000 | 1182 | 0.030 |
Why?
|
| Immunotoxins | 1 | 2012 | 175 | 0.030 |
Why?
|
| District of Columbia | 1 | 1992 | 159 | 0.030 |
Why?
|
| Doxorubicin | 2 | 2010 | 2224 | 0.020 |
Why?
|
| Antigens, CD | 3 | 2007 | 3998 | 0.020 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2011 | 25 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 834 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2015 | 1178 | 0.020 |
Why?
|
| Touch | 1 | 1994 | 310 | 0.020 |
Why?
|
| Neuroblastoma | 2 | 1992 | 1248 | 0.020 |
Why?
|
| SRS-A | 1 | 1991 | 132 | 0.020 |
Why?
|
| Thromboxane B2 | 1 | 1991 | 143 | 0.020 |
Why?
|
| Tissue Preservation | 1 | 1991 | 174 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2001 | 20077 | 0.020 |
Why?
|
| Lymphatic Irradiation | 1 | 2011 | 115 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2012 | 251 | 0.020 |
Why?
|
| Aftercare | 1 | 2017 | 913 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2021 | 2008 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2004 | 3842 | 0.020 |
Why?
|
| Pregnancy | 3 | 2015 | 29869 | 0.020 |
Why?
|
| Mediastinum | 1 | 2012 | 266 | 0.020 |
Why?
|
| Inbreeding | 1 | 2009 | 48 | 0.020 |
Why?
|
| Interferon-gamma | 2 | 2010 | 3145 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1992 | 1376 | 0.020 |
Why?
|
| Cell Survival | 1 | 2000 | 5780 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2012 | 794 | 0.020 |
Why?
|
| Erythrocytes | 2 | 2016 | 2410 | 0.020 |
Why?
|
| Bence Jones Protein | 1 | 2009 | 18 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 3 | 2020 | 7403 | 0.020 |
Why?
|
| Telomere | 1 | 2015 | 942 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 1998 | 6305 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 2009 | 155 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 659 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2015 | 3415 | 0.020 |
Why?
|
| Immunity, Innate | 2 | 2018 | 3045 | 0.020 |
Why?
|
| Body Weight | 1 | 2020 | 4615 | 0.020 |
Why?
|
| Complement C4b | 1 | 2009 | 125 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 3027 | 0.020 |
Why?
|
| Attitude to Health | 1 | 1998 | 2025 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 414 | 0.020 |
Why?
|
| Pseudotumor Cerebri | 1 | 1990 | 108 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 27100 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2009 | 411 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 1990 | 331 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2011 | 400 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 6074 | 0.020 |
Why?
|
| Secondary Prevention | 2 | 2007 | 1470 | 0.020 |
Why?
|
| Lung Diseases, Interstitial | 2 | 1994 | 918 | 0.020 |
Why?
|
| Prednisone | 2 | 2010 | 1562 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2011 | 1156 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1998 | 1909 | 0.020 |
Why?
|
| Mass Screening | 1 | 2024 | 5425 | 0.020 |
Why?
|
| International Cooperation | 1 | 2014 | 1422 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 600 | 0.020 |
Why?
|
| Immunization | 1 | 2012 | 1217 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2018 | 2187 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2012 | 1606 | 0.020 |
Why?
|
| Alanine | 1 | 2010 | 609 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1990 | 349 | 0.020 |
Why?
|
| Azacitidine | 1 | 2009 | 335 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 1990 | 420 | 0.020 |
Why?
|
| Age Factors | 2 | 2015 | 18381 | 0.020 |
Why?
|
| Uric Acid | 1 | 2014 | 806 | 0.020 |
Why?
|
| Macrocyclic Compounds | 1 | 2007 | 68 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 1989 | 464 | 0.020 |
Why?
|
| Receptors, Complement 3b | 1 | 2007 | 135 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 399 | 0.020 |
Why?
|
| Culture Media | 2 | 2004 | 895 | 0.020 |
Why?
|
| Cardiotonic Agents | 1 | 2010 | 539 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 164 | 0.020 |
Why?
|
| Erythroblasts | 1 | 2007 | 142 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 6016 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 1991 | 773 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 1662 | 0.020 |
Why?
|
| Esophageal Stenosis | 1 | 1988 | 197 | 0.020 |
Why?
|
| Gangliosides | 1 | 1987 | 132 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 2625 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2000 | 2778 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1994 | 1116 | 0.020 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2006 | 49 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2011 | 1683 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 11069 | 0.020 |
Why?
|
| Patient Admission | 1 | 1994 | 1365 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 1998 | 1948 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 277 | 0.020 |
Why?
|
| Heart Failure | 1 | 2010 | 11670 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2014 | 9644 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1990 | 557 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2009 | 850 | 0.020 |
Why?
|
| Nephritis, Hereditary | 1 | 2006 | 78 | 0.020 |
Why?
|
| Melanoma | 3 | 1992 | 5696 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 645 | 0.020 |
Why?
|
| Sterilization, Reproductive | 1 | 2005 | 24 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 1895 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2009 | 597 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 1365 | 0.020 |
Why?
|
| Mycophenolic Acid | 1 | 2007 | 348 | 0.020 |
Why?
|
| Cough | 1 | 2009 | 595 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1990 | 1812 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2016 | 2515 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 3451 | 0.020 |
Why?
|
| Plasmacytoma | 1 | 2006 | 171 | 0.020 |
Why?
|
| Genotype | 1 | 2000 | 12977 | 0.020 |
Why?
|
| Daunorubicin | 1 | 1985 | 157 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2010 | 823 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 9417 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1994 | 2894 | 0.020 |
Why?
|
| Immunosorbent Techniques | 1 | 1984 | 174 | 0.020 |
Why?
|
| Oogenesis | 1 | 2005 | 124 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2000 | 5304 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 12448 | 0.010 |
Why?
|
| Hepatitis | 1 | 1986 | 228 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2007 | 908 | 0.010 |
Why?
|
| Base Sequence | 2 | 2009 | 12420 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1990 | 709 | 0.010 |
Why?
|
| Developing Countries | 1 | 2016 | 2868 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 777 | 0.010 |
Why?
|
| Host vs Graft Reaction | 1 | 2003 | 13 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 1990 | 13383 | 0.010 |
Why?
|
| Comorbidity | 1 | 2018 | 10507 | 0.010 |
Why?
|
| Immune System | 1 | 2009 | 791 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2010 | 2635 | 0.010 |
Why?
|
| Monocytes | 2 | 2009 | 2565 | 0.010 |
Why?
|
| Spores, Bacterial | 1 | 2004 | 113 | 0.010 |
Why?
|
| Rabbits | 1 | 2010 | 4770 | 0.010 |
Why?
|
| Platelet Count | 1 | 2006 | 780 | 0.010 |
Why?
|
| Receptors, KIR | 1 | 2003 | 110 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 1994 | 2756 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 1051 | 0.010 |
Why?
|
| Vietnam | 1 | 1984 | 406 | 0.010 |
Why?
|
| Intestines | 1 | 2012 | 1909 | 0.010 |
Why?
|
| Cell Movement | 1 | 2015 | 5201 | 0.010 |
Why?
|
| Preleukemia | 1 | 1982 | 34 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2003 | 199 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1987 | 1642 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1985 | 544 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 2003 | 132 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 12966 | 0.010 |
Why?
|
| Viral Load | 1 | 2011 | 3325 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 1748 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2020 | 12942 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 2639 | 0.010 |
Why?
|
| Phenotype | 1 | 2000 | 16572 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2002 | 310 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2002 | 317 | 0.010 |
Why?
|
| Bilirubin | 1 | 2002 | 435 | 0.010 |
Why?
|
| Ascites | 1 | 2002 | 338 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2009 | 4117 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1995 | 11118 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2001 | 326 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 1614 | 0.010 |
Why?
|
| Oxygen | 1 | 2011 | 4226 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2001 | 767 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 58919 | 0.010 |
Why?
|
| Stem Cell Factor | 1 | 2000 | 195 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 1962 | 0.010 |
Why?
|
| Kinetics | 2 | 2002 | 6370 | 0.010 |
Why?
|
| Spinal Neoplasms | 1 | 1985 | 703 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2015 | 10429 | 0.010 |
Why?
|
| Blood Cells | 1 | 2001 | 305 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6473 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1986 | 1189 | 0.010 |
Why?
|
| Cell Line | 2 | 2009 | 15577 | 0.010 |
Why?
|
| Heparin | 1 | 1986 | 1632 | 0.010 |
Why?
|
| Microspheres | 1 | 2002 | 782 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2000 | 425 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1990 | 4340 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2009 | 2478 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2003 | 1409 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2001 | 531 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2003 | 943 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2009 | 5109 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2010 | 5486 | 0.010 |
Why?
|
| Ureter | 1 | 1999 | 368 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3776 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 2803 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1999 | 901 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1992 | 15829 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2001 | 1730 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2015 | 23974 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 3447 | 0.010 |
Why?
|
| Models, Psychological | 1 | 1998 | 829 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1999 | 1083 | 0.010 |
Why?
|
| Plasma Substitutes | 1 | 1993 | 57 | 0.010 |
Why?
|
| Personal Satisfaction | 1 | 1998 | 645 | 0.010 |
Why?
|
| Lymphokines | 1 | 1996 | 925 | 0.010 |
Why?
|
| United States | 1 | 2021 | 72292 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17878 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 1996 | 341 | 0.010 |
Why?
|
| Family Health | 1 | 1998 | 1253 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 12759 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 9526 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1999 | 1154 | 0.010 |
Why?
|
| Electrolytes | 1 | 1993 | 274 | 0.010 |
Why?
|
| Epitopes | 1 | 1999 | 2501 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1998 | 2925 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1981 | 1406 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1993 | 385 | 0.010 |
Why?
|
| Self Concept | 1 | 1998 | 1046 | 0.010 |
Why?
|
| Ileum | 1 | 1994 | 557 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1990 | 5319 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 15250 | 0.010 |
Why?
|
| Leukotriene E4 | 1 | 1991 | 75 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2009 | 5031 | 0.010 |
Why?
|
| Muscle Cramp | 1 | 1990 | 34 | 0.010 |
Why?
|
| Sex Factors | 1 | 1984 | 10549 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1999 | 3514 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 7583 | 0.010 |
Why?
|
| ROC Curve | 1 | 1998 | 3575 | 0.010 |
Why?
|
| Veterans | 1 | 1984 | 2649 | 0.010 |
Why?
|
| Hybridomas | 1 | 1991 | 442 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 1989 | 215 | 0.000 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1989 | 507 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1998 | 6339 | 0.000 |
Why?
|
| Leukocytes | 1 | 1996 | 2024 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 9586 | 0.000 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1990 | 426 | 0.000 |
Why?
|
| Liver Diseases | 1 | 1996 | 1297 | 0.000 |
Why?
|
| Esophagitis | 1 | 1988 | 165 | 0.000 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1986 | 63 | 0.000 |
Why?
|
| Cystadenocarcinoma | 1 | 1986 | 54 | 0.000 |
Why?
|
| Disease Progression | 1 | 2003 | 13495 | 0.000 |
Why?
|
| Gene Expression | 1 | 1999 | 7569 | 0.000 |
Why?
|
| Myocardium | 1 | 1999 | 4725 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 14649 | 0.000 |
Why?
|
| Leukemia, Lymphoid | 1 | 1985 | 310 | 0.000 |
Why?
|
| DNA | 1 | 1999 | 7196 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1998 | 12043 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2004 | 12116 | 0.000 |
Why?
|
| Antigens | 1 | 1990 | 1441 | 0.000 |
Why?
|
| Cisplatin | 1 | 1990 | 1650 | 0.000 |
Why?
|
| Pain | 1 | 1998 | 5062 | 0.000 |
Why?
|
| Autopsy | 1 | 1986 | 1008 | 0.000 |
Why?
|
| Hysterectomy | 1 | 1986 | 856 | 0.000 |
Why?
|
| Central Nervous System Diseases | 1 | 1985 | 521 | 0.000 |
Why?
|
| Diarrhea | 1 | 1985 | 1317 | 0.000 |
Why?
|
| Life Expectancy | 1 | 1985 | 1242 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1991 | 18937 | 0.000 |
Why?
|